Abstract
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH.
Similar content being viewed by others
Article PDF
References
Archer S, Rich S : Primary pulmonary hypertension: a vascular biology and translational research “work in progress.” Circulation 2000; 102: 2781–2791.
Newman JH : Treatment of primary pulmonary hypertension—the next generation. N Engl J Med 2002; 346: 933–934.
Ghofrani HA, Wiedemann R, Rose F, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895–900.
Beavo JA : Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725–748.
Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ : Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991; 308: 191–197.
Lepore JJ, Maroo A, Pereira NL, et al: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with pulmonary hypertension. Am J Cardiol 2002; 90: 677–680.
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S : Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398–2403.
Cheitlin MD, Hutter AM Jr, Brindis RG, et al: Use of sildenafil (viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168–177.
Zhao L, Mason NA, Morrell NW, et al: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424–428.
Shekerdemian LS, Ravn HB, Penny DJ : Intravenous sildenafil lowes pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 1098–1102.
Kataoka M, Satoh T, Manabe T, et al: Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461–465.
Abrams D, Schulze-Neick I, Magee AG : Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
Michelakis ED, Tymchak W, Noga M, et al: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066–2069.
Watanabe H, Ohashi K, Takeuchi K, et al: Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 71: 398–402.
Corbin JD, Beasley A, Blount MA, Francis SH : Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phoshodiesterase-5 (PDE5). Neurochem Int 2004; 45: 859–863.
Ghofrani HA, Voswinckel R, Reichenberger F, et al: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004; 44: 1488–1496.
Saenz de Tejada I, Angulo J, Cuevas P, et al: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.
Ikeda D, Tsujino I, Ohira H, et al: Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovas Pharmacol 2005; 45: 286–289.
Prasad S, Wilkinson J, Gatzoulis MA : Sildenafil in primary pulmonary hypertension letter. N Engl J Med 2000; 343: 1342.
Wharton J, Strange JW, Moller GM, et al: Anti-proliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Care Med 2005; 172: 105–113.
Heinrike W, Angelika G, Jochem K, et al: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–1222.
Imanishi T, Hano T, Nishio I : Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101–108.
Foresta C, Lana A, Cabrelle A, et al: PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005; 17: 377–380.
Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865–870.
Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H : Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669–676.
Kato J, Kitamura K, Uemura T, et al: Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 2002; 25: 887–892.
Yambe M, Tomita H, Hirayama Y, et al: Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004; 27: 625–632.
Ogata C, Horio T, Kamide K, Takiuchi S, Kawano Y : Association between left ventricular diastolic dysfunction and renal hemodynamic change in patients with treated essential hypertension. Hypertens Res 2003; 26: 971–978.
Takahashi N, Saito Y, Kuwahara K, et al: Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003; 26: 847–853.
Eric R, Evangelos DM, Wayne T, et al: Sildenafil use in patients with the Eisenmenger syndrome. Circulation 2004; 109: 197.
Marius MH, Roman M, Joern T, et al: Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535–541.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aizawa, K., Hanaoka, T., Kasai, H. et al. Long-Term Vardenafil Therapy Improves Hemodynamics in Patients with Pulmonary Hypertension. Hypertens Res 29, 123–128 (2006). https://doi.org/10.1291/hypres.29.123
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.123
Keywords
This article is cited by
-
High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension
European Journal of Clinical Pharmacology (2013)
-
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
International Journal of Impotence Research (2009)
-
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Advances in Therapy (2009)